<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04294069</url>
  </required_header>
  <id_info>
    <org_study_id>20G.119</org_study_id>
    <nct_id>NCT04294069</nct_id>
  </id_info>
  <brief_title>Azithromycin Dose and PPROM Treatment: a Pilot Randomized Controlled Trial</brief_title>
  <acronym>ADAPT</acronym>
  <official_title>Azithromycin Pharmacokinetics and Pharmacodynamics in Pregnancy and Preterm Birth Prevention: Optimizing Dosing to Improve Maternal and Neonatal Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot randomized controlled trial to assess the pharmacokinetics and
      pharmacodynamics of azithromycin in pregnant singletons admitted with preterm premature
      rupture of membranes (PPROM) at 24 0/7- 33 0/7. Participants will be randomized 1:1 to either
      1000mg azithromycin orally once or 500mg azithromycin orally daily for seven days in addition
      to standard care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot randomized controlled trial to assess the pharmacokinetics and
      pharmacodynamics of azithromycin in pregnant singletons admitted with preterm premature
      rupture of membranes (PPROM) at 24 0/7- 33 0/7. Participants will be randomized 1:1 to either
      1000mg azithromycin orally once or 500mg azithromycin orally daily for seven days in addition
      to standard care. During the course of eight days participants will have serial collection of
      amniotic fluid, maternal serum; and at delivery, of placenta, membrane, and cord blood. After
      delivery, neonatal respiratory samples will be collected as well.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Azithromycin trough in amniotic fluid</measure>
    <time_frame>8 days</time_frame>
    <description>Primary outcome is the mean difference in azithromycin trough (Cmin) in amniotic fluid between the two dosing regimens using nonparametric test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IL-6 in amniotic fluid</measure>
    <time_frame>8 days</time_frame>
    <description>Mean difference in IL-6 at delivery or 8 days (which ever is first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-8 in cord blood</measure>
    <time_frame>3 months (delivery)</time_frame>
    <description>Mean difference in IL-8 in cord blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory ureaplasma colonization in neonate</measure>
    <time_frame>3 months</time_frame>
    <description>Culture of nasopharyngeal swab within 48 hours of delivery in neonates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Latency to delivery</measure>
    <time_frame>3 months</time_frame>
    <description>Number days from admission to delivey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-amniotic infection</measure>
    <time_frame>3 months (delivery)</time_frame>
    <description>Incidence of maternal intra-amniotic infection at delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trend in amniotic fluid cytokines</measure>
    <time_frame>8 days</time_frame>
    <description>TNF alpha, IL-1B, IL-6, IL-8 over 8 day period from admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ureaplasma colonization of membranes</measure>
    <time_frame>3 months</time_frame>
    <description>Culture swab taken of membranes after delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histologic chorioamnionitis</measure>
    <time_frame>3 months (delivery)</time_frame>
    <description>incidence of histologic chorioamnionitis in placental pathology</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Preterm Premature Rupture of Membrane</condition>
  <arm_group>
    <arm_group_label>Azithromycin 500mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500mg azithromycin PO daily for seven days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin 1000mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000mg azithromycin PO once at admission</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin 500 mg</intervention_name>
    <description>500mg azithromycin PO for seven days starting on admission</description>
    <arm_group_label>Azithromycin 500mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin Oral Product</intervention_name>
    <description>1000mg azithromycin PO once at admission</description>
    <arm_group_label>Azithromycin 1000mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Singleton gestation 24 0/7 -33 0/7 weeks'

          -  Diagnosed with preterm premature rupture of membranes:

               -  History consistent with ruptured membranes (ie leaking, gush of fluid)

               -  Sterile speculum exam with pooling

               -  Fluid positive for ferning and/or nitrazine

               -  With or without confirmatory test such as Amnisure

        Exclusion Criteria:

          -  â€¢ Contraindication to azithromycin

               -  Active labor, abruption, chorioamnionitis at enrollment

               -  Other contraindication to expectant management of PPROM at enrollment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rupsa C Boelig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rupsa Boelig, MD</last_name>
    <phone>215-955-9196</phone>
    <email>rupsa.boelig@jefferson.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Fetal Membranes, Premature Rupture</mesh_term>
    <mesh_term>Rupture</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD available on request pending completion of data sharing agreement and approval of information requested</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>1 year after publication of results</ipd_time_frame>
    <ipd_access_criteria>IPD available on request pending completion of data sharing agreement and approval of information requested</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

